Regulatory Delays Are Keeping the Diagnostics Industry in Limbo


An FDA official recently stated that the final version of the draft guidance regarding regulation of laboratory-developed tests (LDTs) is not likely to be released before the end of this year.

Elizabeth Mansfield, director of personalized medicine at the FDA’s Center for Devices and Radiological Health, was a panelist at the Clinical Laboratory Association’s annual meeting in March during which she said that additional reviews are required before the final guidance can be issued.

At the same meeting, Marc Hartstein from Centers for Medicare & Medicaid Services (CMS) said that CMS would not meet its deadline to provide a rule about how it will “collect market data and set new rates for Medicare payment of clinical labs.”

These delays affect the two most critical aspects of the IVD industry: LDT regulation and reimbursement. The lingering ambiguity in these areas is a huge drag on investment in new tests, so hopefully resolution is at-hand.


Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access